Fig. 5.

ROS generation via GPIbα and PAR activation is mediated through FAK and NOX1. H₂DCFDA labelled human platelets were pre-treated with the (A) NOX1 inhibitor, 5 µM ML171, or (B) FAK inhibitor, 1 µM PF-228, for 10 min, then stimulated with thrombin (1 U/mL), R543W cells (1:50; cell:platelet ratio) or PAR4-AP (250 µM) for 2 min and monitored for ROS production by flow cytometry. Data are mean±SEM (n=3–6). *P≤0.05, **P≤0.01, ***P≤0.001.